vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and GSK plc (GSK), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.5M | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $8.6M | — | ||
| Q1 24 | $8.2M | — |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | — | ||
| Q2 25 | $-112.0M | — | ||
| Q1 25 | $-89.3M | — | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | — | ||
| Q2 24 | $-96.1M | — | ||
| Q1 24 | $-81.5M | — |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | — | ||
| Q2 25 | -1020.1% | — | ||
| Q1 25 | -1222.0% | — | ||
| Q4 24 | -1165.3% | — | ||
| Q3 24 | -1146.9% | — | ||
| Q2 24 | -1228.3% | — | ||
| Q1 24 | -1124.3% | — |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | — | ||
| Q2 25 | -899.4% | — | ||
| Q1 25 | -1023.3% | — | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | — | ||
| Q2 24 | -1115.7% | — | ||
| Q1 24 | -995.8% | — |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | — | ||
| Q2 25 | $-1.93 | — | ||
| Q1 25 | $-1.55 | — | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | — | ||
| Q2 24 | $-1.69 | — | ||
| Q1 24 | $-1.45 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
